Nogo-A and its receptor have been a target for several blocking experiments after stroke (Lee et al., 2004), spinal cord injury (Liebscher et al., 2005), and in other lesion models that showed beneficial effects of Nogo-A inactivation (reviewed by Overman and Carmichael, 2014; Schwab and Strittmatter, 2014). The gene discussed is RTN4; the disease is stroke disorder.